Pharmaceutical preparation and use thereof
A pharmaceutical preparation includes a first active component, a second active component and pharmaceutically acceptable excipients. The first active component is at least one selected from the group consisting of a neutral endopeptidase inhibitor and a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The second active component is at least one selected from the group consisting of a compound represented by the following formula (I) or a precursor, an active metabolite, a stereoisomer, a pharmaceutically acceptable salt, a prodrug and a solvate thereof. The pharmaceutically acceptable excipients include one or more disintegrants and/or one or more fillers.
1. A pharmaceutical preparation comprising a first active component, a second active component and a pharmaceutically acceptable excipient, wherein said first active component is 4-(((2S,4R)-1-([1,1′-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid or a pharmaceutically acceptable salt thereof;
said second active component is selected from the following compounds:
and
said pharmaceutically acceptable excipients include microcrystalline cellulose and another excipient, wherein said microcrystalline cellulose has a particle size of 95 μm or less.
2. A method for treating a cardiovascular disease, comprising administering the pharmaceutical preparation of claim 1 to a subject in need thereof, wherein said cardiovascular diseases is selected from hypertension, heart failure, chronic heart failure, coronary heart disease, rheumatic heart disease, congenital heart disease, left ventricular dysfunction, endothelial dysfunction, diastolic dysfunction, hypertrophic cardiomyopathy, diabetic cardiomyopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, cardiac fibrosis, atrial flutter, detrimental vascular remodeling, myocardial infarction and sequelae thereof, atherosclerosis, angina, primary and secondary pulmonary hypertension, and renal vascular hypertension.
3. The pharmaceutical preparation of claim 1 , wherein said second active component is selected from the following compound:
4. The pharmaceutical preparation of claim 1 , wherein said microcrystalline cellulose has a particle size of from 10 μm to 90 μm.
5. The pharmaceutical preparation of claim 1 , wherein said microcrystalline cellulose has a particle size of from 15 μm to 85 μm.
6. The pharmaceutical preparation of claim 1 , wherein said microcrystalline cellulose has a particle size of from 20 μm to 85 μm.
7. The pharmaceutical preparation of claim 1 , wherein said microcrystalline cellulose has a particle size of from 20 μm to 75 μm.
8. The pharmaceutical preparation of claim 1 , wherein said pharmaceutically acceptable excipients include a first pharmaceutically acceptable excipient and optionally a second pharmaceutically acceptable excipient;
the first pharmaceutically acceptable excipient comprises said microcrystalline cellulose and at least one selected from a filler and a disintegrant;
said filler is at least one selected from starch, lactose, lactose monohydrate, cellulose-lactose, pregelatinized starch, sucrose, mannitol, sorbitol, calcium phosphate, dextrin, microcrystalline cellulose, calcium hydrogen phosphate and mannitol-starch complex;
said disintegrant is at least one selected from croscarmellose sodium, calcium carboxymethyl cellulose, sodium carboxymethyl starch, methyl cellulose, low-substituted hydroxypropyl cellulose, crospovidone and chitosan; and
the second pharmaceutically acceptable excipient is at least one selected from lubricant, wetting agent, auxiliary lipid, glidant, sweetener, flavoring agent, solvent, cosolvent, suspending agent, isotonic agent, buffers, preservative, antioxidant, colorant, and foaming agent.
9. The pharmaceutical preparation of claim 8 , wherein said lubricant is at least one selected from magnesium stearate, colloidal silica, talc, sodium lauryl sulfate, calcium stearate, polyethylene glycol 4000, polyethylene glycol 6000, sodium stearyl fumarate, glyceryl monostearate and hydrogenated vegetable oil.
10. The pharmaceutical preparation of claim 1 , wherein, in parts by weight, said pharmaceutical preparation comprises:
5 to 40 parts by weight of the first active component,
5 to 40 parts by weight of the second active component,
30 to 70 parts by weight of a filler,
8 to 20 parts by weight of a disintegrant,
0.5 to 5 parts by weight of a lubricant.
11. The pharmaceutical preparation of claim 1 , wherein said first active component and said second active component are at a weight ratio of (0.5-3):1.